Champions Oncology (Champions Oncology) 3-Year Revenue Growth Rate : 13.60% (As of Jan. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Champions Oncology 3-Year Revenue Growth Rate?

Champions Oncology's Revenue per Share for the three months ended in Jan. 2024 was $0.88.

During the past 12 months, Champions Oncology's average Revenue per Share Growth Rate was -7.50% per year. During the past 3 years, the average Revenue per Share Growth Rate was 13.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was 17.60% per year. During the past 10 years, the average Revenue per Share Growth Rate was 9.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Champions Oncology was 66.10% per year. The lowest was -31.00% per year. And the median was 3.30% per year.

Competitive Comparison of Champions Oncology's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Champions Oncology's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Champions Oncology's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Champions Oncology's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Champions Oncology's 3-Year Revenue Growth Rate falls into.

Champions Oncology 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Champions Oncology (NAS:CSBR) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Champions Oncology 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Champions Oncology's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Champions Oncology (Champions Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Champions Oncology Inc (NAS:CSBR) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

2I3:Germany

Address

One University Plaza, Suite 307, Hackensack, NJ, USA, 07601

Website

https://www.championsoncology.com

Champions Oncology Inc is a us-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies.

Executives

Daniel Newman Mendelson	director	COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR, SUITE 900, BETHESDA MD 20817
Ronnie Morris	director, officer: President	855 N. WOLFE STREET, SUITE 619, BALTIMORE MD 21205
Philip P. Breitfeld	director	ONE UNIVERSITY PLAZA, SUITE 307, HACKENSACK NJ 07601
New Enterprise Associates 14, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Neeraj Agrawal	10 percent owner	ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Roger H Lee	10 percent owner	ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Michael Maurice Brown	10 percent owner	ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Battery Management Corp.	10 percent owner	ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
R David Tabors	10 percent owner	ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Jesse Feldman	10 percent owner	ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Joel Ackerman	director, officer: Chief Executive Officer	COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR SUITE 900, BETHESDA MD 20817
Patrick J Kerins	10 percent owner
Ryan D Drant	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Nea 14 Gp, Ltd	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 14, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093